Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442714 · ClinicalTrials.gov registry record · Phase 2
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01442714: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT01442714 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01442714, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and lenalidomide.
Interventions
- DRUG Azacitidine
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442714
The ClinicalTrials.gov registry entry for NCT01442714 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT01442714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442714 about?
NCT01442714 is a clinical study titled "Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS". The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and lenalidomide.
What is the current status of trial NCT01442714?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2011-08. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01442714?
The interventions under investigation include: Azacitidine (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01442714?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.